Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

A PATHOLOGICAL COMPLETE RESPONSE ("PCR") HAS BEEN OBSERVED IN THE FIRST PATIENT EVALUATED IN COHORT A, WHERE EACH PATIENT RECEIVES TWO DOSES OF INT230-6 EIGHT DAYS APART, FOLLOWED BY THE STANDARD OF CARE IMMUNOCHEMOTHERAPY ("SOC") SAFETY LOOKS FAVORABLE IN COHORT A SOME INT230-6 PATIENTS BEGIN TO SHOW LOCALIZED SKIN IRRITATION, AND NEW PATIENT ENROLLMENT HAS BEEN PAUSED TO IMPLEMENT MODIFICATIONS TO RESOLVE THE ISSUE PATIENTS BEING TREATED WITH INT230-6 CONTINUE TO SHOW SIGNIFICANT NECROSIS AFTER TWO DOSES OF INT230-6 AND PRIOR TO THE INITIATION OF THE SOC, AS SHOWN IN THE PHOTOS BELOW OF A SINGLE PATIENT'S BREAST TUMOR SCANS SHELTON, CONN. , SEPT. 10, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY PROVIDED AN UPDATE ON THE INVINCIBLE-4 TRIAL.

INTENSITY THERAPEUTICS REPORTS INVINCIBLE-4, PRESURGICAL TRIPLE-NEGATIVE BREAST CANCER STUDY UPDATE

SHELTON, CONN. , SEPT. 2, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES THAT IT WILL PARTICIPATE IN THE H.C.

INTENSITY THERAPEUTICS, INC. TO PARTICIPATE IN FIRESIDE CHAT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

SHELTON, CONN. , AUG. 12, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES THAT THE COMPANY RECEIVED A LETTER FROM THE LISTING QUALIFICATIONS STAFF (THE "STAFF") OF THE NASDAQ STOCK MARKET LLC ("NASDAQ") STATING THAT THE STAFF HAS DETERMINED THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT.

INTENSITY THERAPEUTICS, INC. REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT

OVER $11 MILLION RAISED SINCE THE BEGINNING OF 2Q 2025 CASH RUNWAY EXTENDED INTO THE SECOND HALF OF 2026 IN THE INVINCIBLE-4 STUDY, PATIENTS RECEIVING INT230-6 PRIOR TO THE START OF STANDARD OF CARE ACHIEVED HIGH LEVELS OF TUMOR NECROSIS IN 8 DAYS INT230-6 ACHIEVED 100% COMPLETE RESPONSE RATE IN PRECLINICAL MODELS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS SHELTON, CONN. , AUG. 7, 2025 /PRNEWSWIRE/ --INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.

INTENSITY THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CASH RUNWAY EXTENDED INTO THE SECOND HALF OF 2026 AVERAGE SALES PRICE PER SHARE WAS OVER 10% HIGHER THAN THE JUNE 2025 PUBLIC OFFERING PRICE SHELTON, CONN. , AUG. 4, 2025 /PRNEWSWIRE/ --INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES THAT IN JULY 2025 THE COMPANY ADDED $6.6 MILLION IN GROSS PROCEEDS ($6.3 MILLION NET) BY SELLING 19,868,658 SHARES OF ITS COMMON STOCK VIA ITS AT-THE-MARKET OFFERING (THE "ATM") AT AN AVERAGE PRICE OF $0.3323 PER SHARE.

INTENSITY THERAPEUTICS, INC. RAISES $6.6 MILLION FROM AT THE MARKET OFFERING (ATM) STOCK SALES IN JULY 2025

SHELTON, CONN. , JUNE 30, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR "THE COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY, NOVEL IMMUNE-BASED INTRATUMORAL CANCER THERAPIES DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES THAT INT230-6 ACHIEVED COMPLETE RESPONSES IN A MURINE MODELS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR ("MPNST").

INTENSITY THERAPEUTICS, INC. ANNOUNCES THAT INT230-6 ACHIEVED 100% COMPLETE RESPONSE RATE IN PRECLINICAL MODELS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)

SHELTON, CONN. , JUNE 11, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY, NOVEL IMMUNE-BASED INTRATUMORAL CANCER THERAPIES DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS,TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 6,675,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $0.30 PER SHARE, FOR GROSS PROCEEDS OF $2,002,500, BEFORE DEDUCTING UNDERWRITING DISCOUNTS, COMMISSIONS AND OFFERING EXPENSES.

INTENSITY THERAPEUTICS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING

SHELTON, CONN. , JUNE 11, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY, NOVEL IMMUNE-BASED INTRATUMORAL CANCER THERAPIES DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, TODAY ANNOUNCED THAT IT INTENDS TO OFFER TO SELL SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

INTENSITY THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

SHELTON, CONN. , JUNE 11, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY, NOVEL IMMUNE-BASED INTRATUMORAL CANCER THERAPIES DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES FIRST FEW PATIENTS RECEIVING INT230-6 ACHIEVED HIGH LEVELS OF NECROSIS AFTER 8 DAYS IN THE PHASE 2, INVINCIBLE-4 STUDY, BEFORE THEY INITIATED THE STANDARD-OF-CARE REGIMEN AS SHOWN IN FIGURE 1.

INTENSITY THERAPEUTICS, INC. ANNOUNCES PATIENTS RECEIVING INT230-6 PRIOR TO THE START OF STANDARD-OF-CARE MAY ACHIEVE HIGH LEVELS OF TUMOR NECROSIS IN THE ONGOING RANDOMIZED CONTROLLED PHASE 2 INVINCIBLE-4 STUDY

SHELTON, CONN. , MAY 29, 2025 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY"OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY, NOVEL IMMUNE-BASED INTRATUMORAL CANCER THERAPIES DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES THAT THE COMPANY WILL BE PRESENTING A TRIALS IN PROGRESS POSTER OUTLINING ITS PHASE 3 INVINCIBLE-3 CLINICAL TRIAL OF INT230-6 FOR THE TREATMENT OF METASTATIC SOFT TISSUE SARCOMAS.

INTENSITY THERAPEUTICS, INC.'S PHASE 3 INVINCIBLE-3 SARCOMA STUDY SELECTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2025 ANNUAL MEETING

Intensity Therapeutics, Inc.

INTS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Intensity Therapeutics, Inc.

INTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INTS